Palmitoylethanolamide

Palmitoylethanolamide lowers the risk of depressive symptom severity in humans (β = -0.27, 95% CI [-0.49, -0.05], p = 0.01).

Humansperimenopausal women with untreated mild-to-moderate depressive symptoms8 weeksfemalesn = 38

Associations of endocannabinoids and related lipid mediators with depressive symptoms during perimenopause · Psychoneuroendocrinology · 12 Sep 2026